TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma.
TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma.
复制标题
TACE联合经皮化疗-碘油治疗不可切除的带蒂肝细胞癌
DOI：
10.1097/md.0000000000007650
复制
发表时间：
2017-07
期刊：
影响因子：
1.6
通讯作者：
Li Y
中科院分区：
文献类型：
--
作者：
Huang D;Chen Y;Chen S;Zeng Q;Zhao J;Wu R;Li Y
摘要带蒂肝细胞癌（P-HCC）是一种少见的原发性肝癌。本研究旨在评价经导管动脉化疗栓塞（TACE）和经皮化疗药物阿曲碘油乳剂（CALE）注射治疗不可切除的P-HCC的临床特征和结局。回顾性分析25例经肝动脉化疗栓塞（TACE）联合经皮肝动脉栓塞（CALE）治疗不能切除的原发性肝癌（P-HCC）患者的临床特点和疗效，并分析影响疗效的相关因素。还与无蒂不可切除的肝癌进行了比较。患者接受了中位4次TACE治疗，接受了中位2次经皮CALE注射。P-HCC患者的1、2、3和5年精算生存率分别为78.9%、52.6%、42.1%和12.0%，中位生存期为27个月（95%置信区间，22.6-43.2个月）。P-HCC患者的总生存率高于无蒂HCC（NP-HCC）患者（P = 0.002）。 血管侵犯和腹腔淋巴结转移是影响P-HCC患者总生存率的不良预后因素。TACE联合经皮CALE注射是治疗不能切除的P-HCC安全有效的方法。不能切除的P-HCC患者在TACE联合经皮CALE注射后的总生存率可能高于NP-HCC患者。然而，他们的预后仍然很差。
Abstract Pedunculated hepatocellular carcinoma (P-HCC) is rare type of HCC. The study aimed to evaluate the clinical features and outcomes of unresectable P-HCC treated with transcatheter arterial chemoembolization (TACE) and percutaneous chemotherapeutic agents lipiodol emulsion (CALE) injection. The clinical features and outcomes of 25 patients with unresectable P-HCC treated with TACE plus percutaneous CALE injection were retrospectively reviewed, and factors associated with outcomes were analyzed. Comparison with nonpedunculated unresectable HCC was also performed. Patients underwent a median of 4 TACE sessions and received a median of 2 percutaneous CALE injections. The 1-, 2-, 3-, and 5-year actuarial survival rates were 78.9%, 52.6%, 42.1%, and 12.0%, respectively, for patients with P-HCC, and median survival was 27 months (95% confidence interval, 22.6–43.2 months). Patients with P-HCC had better overall survival than those with nonpedunculated HCC (NP-HCC) (P = .002). Vascular invasion and abdominal lymph node metastasis were poor prognostic factors for overall survival in patients with P-HCC. TACE plus percutaneous CALE injection is a safe and effective treatment for unresectable P-HCC. Patients with unresectable P-HCC might have better overall survival than those with NP-HCC after TACE plus percutaneous CALE injection. However, their prognosis remains poor.
影响因子：
4.8
作者：
Huang D;Chen Y;Zeng Q;Wu R;Li Y
通讯作者：
Li Y